ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Role of CAR-T Cell Therapy in Post Transplant Lymphoproliferative Disorder

S. Krishnamoorthy, A. Malone, R. Delos Santos, H. Murad, T. Alhamad

Transplant, Washington University in St. Louis, Saint Louis, MO

Meeting: 2020 American Transplant Congress

Abstract number: 504

Keywords: Epstein-Barr virus (EBV), Post-transplant lymphoproliferative disorder (PTLD), T cells

Session Information

Date: Saturday, May 30, 2020

Session Name: PTLD/Malignancies

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

Related Abstracts
  • B Cell MicroRNA as Biomarkers for Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder
  • Epstein Barr Virus DNA Integration in B Cell Lymphomas of Post-Transplant Lymphoproliferative Disorder

*Purpose: Chimeric Antigen Receptor (CAR) T cells are a genetically modified autologous immunotherapy that uses a patient’s own T cells modified with a chimeric antigen receptor that directs it against lymphoma cells. Though CAR-T cells have shown activity against diffuse large B cell lymphomas (DLBCL) in patients who have second or later relapses or are chemo-resistant to salvage therapy, its use and outcomes in solid organ recipients with post transplant lymphoproliferative disorder (PTLD) have not been defined. Using this case series, we review our experience with CAR-T cell therapy in solid organ transplant recipients at our center.

*Methods: Retrospective review of electronic medical records of solid organ transplant recipients who received CAR-T therapy between January 2018 and November 2019.

*Results: 4 cases identified. 2 cases of orthotopic heart transplant (OHT), 1 case of deceased donor kidney transplant and 1 case of pancreas after kidney transplant (PAK). These patients developed PTLD about 10-20 years after their transplant. All patients showed progression of disease without remission after first and second line chemotherapy. Only 1 of the patients had EBV positive PTLD and was treated with EBV cytotoxic T cell therapy, while the other 3 underwent pheresis and proceeded to get CAR-T cell therapy. All patients developed cytokine release syndrome, neurotoxicity and received tocilizumab. 3 out of 4 patients developed AKI requiring renal replacement therapy (RRT). Only 1 of these 3 recovered renal function. All 3 patients who required RRT either transitioned to hospice or deescalated care and did not survive. The PAK patient who developed acute pancreatitis post immunotherapy without kidney injury has shown continued response to therapy without new lymphomatous involvement 90 days after CAR-T therapy.

*Conclusions: This series identifies the challenges of managing PTLD and immunosuppression in solid organ recipients with CAR-T therapy given poor outcomes and significant toxicity in this subgroup.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Krishnamoorthy S, Malone A, Santos RDelos, Murad H, Alhamad T. Role of CAR-T Cell Therapy in Post Transplant Lymphoproliferative Disorder [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/role-of-car-t-cell-therapy-in-post-transplant-lymphoproliferative-disorder/. Accessed April 15, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Direct Oral Anticoagulation Use in Kidney Transplant Recipients

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy | Terms of Use

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.